Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization
Co-delivery of a novel lipidated TLR7/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses
Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD
Using Dual Toll-like Receptor Agonism to Drive Th1-BiasedResponse in a Squalene- andα-Tocopherol-ContainingEmulsion for a More Effective SARS-CoV-2 Vaccine
A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models
Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization
Co-delivery of a novel lipidated TLR7/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses
Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD
Using Dual Toll-like Receptor Agonism to Drive Th1-BiasedResponse in a Squalene- andα-Tocopherol-ContainingEmulsion for a More Effective SARS-CoV-2 Vaccine
A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models
